Accelerating Potential
First-in-Class Therapeutics
NYB Therapeutics bridges botanical complexity and innovative medicine to deliver clinically validated programs. We are advancing three active programs in oncology, cardiovascular, and mood disorders.
We utilize Vecura, our AI-first discovery platform, to decode centuries of human-use signals found in traditional medicine systems. By applying proprietary models to Vecurate, one of the world's largest natural compound libraries, we compress the discovery timeline and deliver high-potential assets optimized for global co-development.
AI meets Nature. Medicine reimagined.
Our AI-prioritized selection achieves a 40% hit rate—up to 40x higher than traditional virtual screening. For natural-product programs, it takes less than three years from plant to preclinical candidate (PCC), almost half of the industry average.
We deliver potentially first-in-class assets optimized for global licensing and co-development, defined by:
Botanical Signal. Predictive Scale
We bridge the gap between pure-play AI (starting from scratch) and traditional natural-product shops (lacking scale). By applying Vecura to natural compounds with centuries of human-use signals, we compress the discovery timeline.
Bench-to-bedside execution
Most AI discovery firms stop at hit identification and license out. NYB takes assets through preclinical compound (PCC), IND and Phase 1. Partners acquire clinically validated programs, not just theoretical leads.
.avif)
Our Value Chain
From Source to Partnership
Stage 1
Discovery: Source to Validated Hit
- Natural Compounds: Decode traditional plant medicine using Vecurate, our massive digital library of natural compounds. It classifies over 1.5 million molecules from 50,000 underexplored Southeast Asian species, bridging ethnobotanical knowledge with molecular bioactivity to fuel pharmaceutical discovery.
- AI Compound Triage: While pure-play AI biotechs start with scratch chemistries, we utilize Vecura, our AI-first computational backbone, to decode these signals and compress R&D timelines via validated biological starting points, screening and prioritizing candidates with the highest potential for therapeutic intervention.
- Hit Identification: Every AI-prioritized lead undergoes rigorous wet-lab testing to confirm biological activity and establish a validated hit.
Stage 2
Development: Hit to Preclinical Candidate
- Hit-to-Lead: Conduct Structure-Activity Relationship (SAR) analysis in the lab to refine potency and selectivity.
- Lead Optimization: Utilize an iterative loop between the Vecura engine and wet-lab testing to continuously optimize leads for efficacy and safety.
- PCC Selection: Selection of a high-confidence PCC ready for advanced studies.
Stage 3
Clinical & Deal: PCC to Partnership
- IND-Enabling: Manage the transition to clinical readiness through Good Laboratory Practice (GLP) toxicology and Chemistry, Manufacturing, and Controls (CMC) development.
- Phase 1: Most AI discovery firms stop at hit ID and license out. NYB takes assets through PCC, IND and Phase 1, meaning partners buy de-risked, clinically validated programs, not paper compounds.
- Partnership: NTU collaboration provides scientific rigor and IP-grade validation. Our global CRO network provides the GLP/GMP execution capacity required for clinical-grade results.
Lead Asset Spotlight
NB-A002
Targeting DNA Repair Vulnerabilities in Cancer
NB-A002 is a potentially first-in-class therapeutic candidate designed to address a critical gap in oncology treatment.
The Challenge
DNA damage response (DDR), especially homologous recombination (HRD) positive cancers often develop resistance to standard therapies such as PARP inhibitors and platinum-based chemotherapy, leading to limited treatment options and poor patient outcomes.
NB-A002 targets the previously undruggable ILF2 protein, leveraging a novel mechanism to induce synthetic lethality through transcription–replication conflicts.
This enables
- Selective targeting of DNA damage response (DDR)-deficient cancers
- A differentiated strategy beyond existing PARP-based approaches
- Potential application across multiple oncology indications
Note: NYB assigned the full ownership of Singapore provisional patents for drug candidates. Patents pending in key markets such as the U.S. EU, China and Japan.
Built for Collaboration
We deliver IP-grade validation through our embedded academic partnership with NTU and a global CRO network. Every program is structured for seamless licensing or co-development, providing:
- Clean data packages and regulatory-grade documentation
- Faster access to validated candidates at a fraction of traditional costs
- Defensible IP built on a foundation of scientific rigor
